Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and the Nasdaq Composite lost 1.3%.
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection shortage.
Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
Why Hims & Hers Stock Dropped Today
Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning. Raising its price target on the shares to $21,
HIMS Stock: Is The Risk Worth The Reward?
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely
Hims & Hers Health Stock Hits All-Time Highs: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab testing. Positive analyst coverage may also be boosting the stock. Here's what you need to know.
Why Hims & Hers Health Stock Is Skyrocketing Today
Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m. ET, and was up as much as 24.8% earlier in the day. The gain comes as the S&P 500 gained 0.1%, and the Nasdaq Composite was flat.
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Modern Healthcare2h
Hims & Hers' stock tanks as semaglutide shortage ends
The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers: A Glorious Opportunity To Trim (Rating Downgrade)
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...